Product Image

Contributor Information

  • Name Marie McIlroy
  • Institute Royal College of Surgeons Ireland (RCSI)

Tool Details

  • Tool name: MCF7aro Let-R Cell Line
  • Tool type: Cell Lines
  • Tool sub-type: Continuous
  • Parental cell line: MCF7
  • Organism: Human
  • Tissue: Breast
  • Cancer type: Breast cancer
  • Disease: Cancer
  • Model: Tumour line
  • Conditional: Yes
  • Description: MCF7aro Let-R Cell Line is a human cell line model of aromatase inhibitor resistant breast cancer.
  • Research area: Cancer; Drug development
  • Production details: Letrozole (aromatase inhibitor) sensitive cells (MCF-7aro) were developed by stable transfection of the aromatase gene (CYP19); Letrozole-resistant cells (MCF-7aro Let-R) were created by long-term treatment of aromatase-expressing MCF7 cells (MCF7aro) with letrozole.
  • Cellosaurus ID: CVCL_W348

  • For Research Use Only

Target Details

  • Target: Aromatase expressing, Letrozole resistant

Application Details

Handling

  • Format: Frozen
  • Growth medium: They are cultured in phenol red free Eagle's Minimum Essential Medium (Phenol-red free MEM) (Sigma Aldrich), 10% charcoal dextran stripped FCS (CDS-FCS), 1% Pen-Strep (Sigma Aldrich), 2 mM L-Glutamine (Sigma Aldrich) and 200 ?„?žg/ml G418 disulfate salt (Geneticin) (Sigma Aldrich), 2.5-8 M androstenedione and 10-6 M letrozole.
  • Storage conditions: Liquid Nitrogen
  • Shipping conditions: Dry ice
  • Mycoplasma free: Yes
  • Biosafety level: 1

Documentation

Related Tools

Product Image

C75 Colorectal adenocarcinoma Cell Line

#151758
Product Image

Halo nevus Melanocyte Cell Line

#154105
Product Image

BCH-RB54 Retinoblastoma cell line

#160602

References

  • •  Cellosaurus MCF-7aro Let-R (CVCL_W348)
  • •  O'Hara et al. 2012. Clin Cancer Res. 18(12):3305-15. PMID: 22550166.
  • •  AIB1:ERa transcriptional activity is selectively enhanced in aromatase inhibitor-resistant breast cancer cells.
  • •  McIlroy et al. 2010. Cancer Res. 70(4):1585-94. PMID: 20145129.
  • •  Interaction of developmental transcription factor HOXC11 with steroid receptor coactivator SRC-1 mediates resistance to endocrine therapy in breast cancer [corrected].